The risk of hepatocellular carcinoma (HCC) is not completely eliminated in chronic hepatitis C (CHC) patients even after viral eradication. There are few studies in predicting the development of HCC using biomarker in CHC patients with sustained virologic response (SVR). We evaluated the role of the aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) in predicting HCC development in 295 patients with SVR after interferon therapy. The annual incidence of HCC was 0.55% (95% confidence interval: 0.31-0.96). It was higher in patients with a pretreatment APRI ≥2.0 than in those with an APRI <2.0 (1.82% versus 0.17%; P = 0.0001) and in patients with a FIB-4 ≥ 3.25 compared with those with a FIB-4 < 3.25. (1.50% versus 0.07%; P = 0.0001). The annual incidence of HCC was higher in patients with a post-treatment APRI ≥0.5 than in those with an APRI <0.5 (1.67% versus 0.07%; P < 0.0001) and in patients with a post-treatment FIB-4 ≥ 2.5 compared with those with a FIB-4 < 2.5 (1.49% versus 0.01%; P = 0.0003). Among pretreatment variables, male gender, albumin, APRI, or FIB-4 were independent predictors for HCC. Among post-treatment variables, APRI or FIB-4 was an independent predictor for HCC. HCC surveillance should be performed in these high-risk patients.

中文翻译：

---

天冬氨酸转氨酶与血小板的比率或Fibros-4指数预测了对干扰素治疗具有持续病毒学应答的慢性丙型肝炎患者肝细胞癌的发展。

甚至在消灭病毒后，慢性丙型肝炎（CHC）患者的肝细胞癌（HCC）风险也不能完全消除。很少有研究使用生物标志物预测具有持续病毒学应答（SVR）的CHC患者的肝癌发展。我们评估了295例SVR患者接受干扰素治疗后，天冬氨酸转氨酶与血小板比指数（APRI）和纤维化4指数（FIB-4）在预测HCC发生中的作用。肝癌的年发生率为0.55％（95％置信区间：0.31-0.96）。预处理APRI≥2.0的患者高于APRI <2.0的患者（1.82％比0.17％； P = 0.0001），FIB-4≥3.25的患者高于FIB-4 <3.25的患者。（1.50％对0.07％； P = 0.0001）。治疗后APRI≥0.5的患者的HCC年发生率高于治疗后APRI <0.5的患者（1.67％对0.07％; P <0.0001）和治疗后FIB-4≥2.5的患者的HCC年发病率更高FIB-4 <2.5的受访者（1.49％比0.01％； P = 0.0003）。在预处理变量中，男性，白蛋白，APRI或FIB-4是HCC的独立预测因子。在治疗后的变量中，APRI或FIB-4是肝癌的独立预测因子。这些高危患者应进行HCC监测。在治疗后的变量中，APRI或FIB-4是肝癌的独立预测因子。这些高危患者应进行HCC监测。在治疗后的变量中，APRI或FIB-4是肝癌的独立预测因子。这些高危患者应进行HCC监测。